Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Inflammatory-endocrine state tied to muscle quality decline in elderly Asians

Tristan Manalac
30 Nov 2017

In elderly adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer’s disease (AD), malnutrition appears to lead to progress muscle mass loss, reveals a new Singapore study, which also identifies a proinflammatory state combined with endocrine deficiency as a risk factor for declining muscle quality ending in sarcopoenia.

“While malnutrition is a precursor for progressive loss of muscle mass, being the common risk factor for presarcopoenia and sarcopoenia, a combined proinflammatory and endocrine-deficient state aggravates decline in muscle performance culminating in frank sarcopoenia,” researchers said.

Moreover, the current study “supports the clinical relevance of muscle quality beyond muscle mass as a determinant of functional performance in cognitively impaired older adults,” they added.

The research team recruited 129 elderly adults (mean age 76.6±6.5 years; 64.8 percent female) with baseline diagnoses of MCI or mild-to-moderate AD from the Tan Tock Seng Hospital in Singapore.

Muscle quality of the participants was measured using grip strength, knee extensor muscle strength, gait speed and dual-energy X-ray absorptiometry. The Chinese version of the mini-mental state examination (CMMSE) and the clinical dementia rating (CDR) were used to evaluate cognitive performance and dementia severity.

Based on the European working group on sarcopoenia in older people (EWGSOP) criteria, participants were divided into three groups: no sarcopoenia (n=41; mean age 76.2±5.5 years), presarcopoenia (n=14; mean age 72.4±7.5 years) and sarcopoenia (n=53; mean age 78.3±6.5 years). [Arch Gerontol Geriatr 2017;75:20-27s]

In multinomial logistic regression analysis adjusted for covariates such as age and gender, the risk of malnutrition was significantly higher in participants with presarcopoenia (relative risk ratio, 7.53; 95 percent CI, 1.20 to 47.51; p=0.032) and sarcopoenia (relative risk ratio, 11.91; 2.85 to 49.77; p=0.001) than in those without sarcopoenia.

While either did not pass as risk factors individually, the combined state of being proinflammatory and endocrine-deficient were significantly associated with elevated risks of sarcopoenia (relative risk ratio, 5.17; 1.31 to 20.37; p=0.019). The inflammatory-endocrine state was not associated with sarcopoenia in any way.

The findings of the current study confirm the importance of nutrition in maintaining muscle quantity and quality, as reported widely in the literature. However, because nutritional status could not completely account for rates of physical frailty, researchers hypothesized that there were other factors that drove muscle quality decline.

“While optimizing nutritional status will undoubtedly remain important to prevent progressive loss of muscle mass, more targeted interventions that simultaneously address immune and endocrine dysfunctions will be necessary to ensure maintenance of functional independence through preserving muscle quality,” they said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.